The phenotype of gut endocrine tumours

Digestive and Liver Disease

Volumn 36, Issue SUPPL. 1, 2004, Pages

  Rindi, G ^a   Ubiali, A ^b   Villanacci, V ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Chromogranin A; Endocrine cells; Gut; Immunohistochemistry; MEN1; NSE; Pancreas; PGP9.5; Synaptophysin

Indexed keywords

CELL MARKER; CHROMOGRANIN A; GENE PRODUCT; KI 67 ANTIGEN; NEURON SPECIFIC ENOLASE; PROTEIN P53; SYNAPTOPHYSIN; VESICULAR MONOAMINE TRANSPORTER 1; VESICULAR MONOAMINE TRANSPORTER 2; TUMOR MARKER;

CANCER CLASSIFICATION; CANCER GRADING; CARCINOGENESIS; CARCINOID; CELL ORGANELLE; CYTOSOL; DIGESTIVE SYSTEM CANCER; DISEASE ACTIVITY; ENDOCRINE CELL; ENDOCRINE TUMOR; GENE MUTATION; HISTOPATHOLOGY; HORMONE SYNTHESIS; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA; PANCREAS CANCER; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; SYNAPSE; TUMOR CELL; TUMOR DIFFERENTIATION; CLASSIFICATION; GASTROINTESTINAL TUMOR; GENETICS;

ENDOCRINE GLAND NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HUMANS; PHENOTYPE; TUMOR MARKERS, BIOLOGICAL;

EID: 2442716589     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2003.11.010     Document Type: Article

References (54)

1. Solcia E, Rindi G, Capella C. Neuroendocrine tumours and hyperplasias. In: Filipe MI, Lake BD, editors. Histochemistry in pathology. London, New York, Melbourne: Churchill-Livingstone; 1991. p. 397-409.
2. Rindi G, Capella C, Solcia E. Pathobiology and classification of digestive endocrine tumours. In: Mignon M, Colombel JF, editors. Recent advances in the pathophysiology of inflammatory bowel disease and digestive endocrine tumours. Montrouge, London, Rome: John Libbey Eurotext; 1999. p. 177-91.
3. Rehfeld JF. The new biology of gastrointestinal hormones. Physiol Rev 1998;78:1087-108.
4. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985;315:115-22.
5. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-60.
6. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994;367:375-6.
7. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997;276:404-7.
8. Solcia E, Klöppel G, Sobin LH. Histological typing of endocrine tumours. In: World Health Organization Edition. International histological classification of endocrine tumours. New York: Springer-Verlag; 2000.
9. Kleihues P, Cavenee WK. Pathology and genetics of the tumours of the nervous system. World Health Organization Classification of Tumours. Lyon: IARC Press; 2000.
10. Larsson LI, Goltermann N, de Magistris L, Rehfeld JF, Schwartz TW. Somatostatin cell processes as pathways for paracrine secretion. Science 1979;205:1393-5.
11. Sporn MB, Todaro GJ. Autocrine secretion and malignant transformation of cells. N Engl J Med 1980;303:878-80.
12. Sporn MB, Roberts AB. Autocrine growth factors and cancer. Nature 1985;313:745-7.
13. Wiedenmann B, John M, Ahnert-Hilger G, Riecken EO. Molecular and cell biological aspects of neuroendocrine tumours of the gastroenteropancreatic system. J Mol Med 1998;76:637-47.
14. Lloyd RV, Wilson BS. Specific endocrine tissue marker defined by a monoclonal antibody. Science 1983;222:628-30.
15. Rindi G, Buffa R, Sessa F, Tortora O, Solcia E. Chromogranin A, B and C immunoreactivities of mammalian endocrine cells. Distribution, distinction from costored hormones/prohormones and relationship with the argyrophil component of secretory granules. Histochemistry 1986;85:19-28.
16. Wiedenmann B, Franke WW. Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles. Cell 1985;41:1017-28.
17. Jahn R, Schiebler W, Ouimet C, Greengard P. A 38,000-dalton membrane protein (p38) present in synaptic vesicles. Proc Natl Acad Sci USA 1985;82:4137-41.
18. Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA 1996;93:5166-71.
19. Kolby L, Wangberg B, Ahlman H, Jansson S, Forssell-Aronsson E, Erickson JD, et al. Gastric carcinoid with histamine production, histamine transporter and expression of somatostatin receptors. Digestion 1998;59:160-6.
20. Eissele R, Anlauf M, Schafer MK, Eiden LE, Arnold R, Weihe E. Expression of vesicular monoamine transporters in endocrine hyperplasia and endocrine tumours of the oxyntic stomach. Digestion 1999;60:428-39.
21. Rindi G, Paolotti D, Fiocca R, Wiedenmann B, Henry JP, Solcia E. Vesicular monoamine transporter 2 as a marker of gastric enterochromaffin-like cell tumours. Virchows Arch 2000;436:217-23.
22. Tapia FJ, Polak JM, Barbosa AJ, Bloom SR, Marangos PJ, Dermody C, et al. Neuron-specific enolase is produced by neuroendocrine tumours. Lancet 1981;1:808-11.
23. Bishop AE, Polak JM, Facer P, Ferri GL, Marangos PJ, Pearse AG. Neuron specific enolase: a common marker for the endocrine cells and innervation of the gut and pancreas. Gastroenterology 1982;83:902-15.
24. Rode J, Dhillon AP, Doran JF, Jackson P, Thompson RJ. PGP 9.5, a new marker for human neuroendocrine tumours. Histopathology 1985;9:147-58.
25. Wilkinson KD, Lee KM, Desphande S, Duerksen-Hughes P, Boss JM, Pohl J. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 1989;246:670-3.
26. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656-60.
27. Rindi G, Necchi V, Savio A, Torsello A, Zoli M, Locatelli V, et al. Characterisation of gastric ghrelin cells in man and other mammals: studies in adult and fetal tissues. Histochem Cell Biol 2002;117:511-9.
28. Levi F, Te VC, Randimbison L, Rindi G, La Vecchia C. Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974-1997. Br J Cancer 2000;83:952-5.
29. Solcia E, Capella C, Klöppel G. Tumours of the pancreas. In: Rosai J, editor. Atlas of tumour pathology, Fascicle 7. Washington, DC: Armed Force Institute of Pathology; 1997.
30. Solcia E, Capella C, Fiocca R, Sessa F, LaRosa S, Rindi G. Disorders of the endocrine system. In: Ming S-C, Goldman H, editors. Pathology of the gastrointestinal tract. Philadelphia: Williams and Wilkins; 1998. p. 295-322.
31. Rindi G, Azzoni C, La Rosa S, Klersy C, Paolotti D, Rappel S, et al. ECL cell tumour and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 1999;116:532-42.
32. Chaudhry A, Oberg K, Wilander E. A study of biological behaviour based on the expression of a proliferating antigen in neuroendocrine tumours of the digestive system. Tumour Biol 1992;13:27-35.
33. La Rosa S, Sessa F, Capella C, Riva C, Leone BE, Klersy C, et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch 1996;429:323-33.
34. Pelosi G, Bresaola E, Bogina G, Pasini F, Rodella S, Castelli P, et al. Endocrine tumours of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol 1996;27:1124-34.
35. Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993;104:994-1006, see comments.
36. Rigaud G, Missiaglia E, Moore PS, Zamboni G, Falconi M, Talamini G, et al. High resolution allelotype of nonfunctional pancreatic endocrine tumours: identification of two molecular subgroups with clinical implications. Cancer Res 2001;61:285-92.
37. Park JG, Choe GY, Helman LJ, Gazdar AF, Yang HK, Kim JP, et al. Chromogranin-A expression in gastric and colon cancer tissues. Int J Cancer 1992;51:189-94.
38. Chejfec G, Capella C, Solcia E, Jao W, Gould VE. Amphicrine cells, dysplasias, and neoplasias. Cancer 1985;56:2683-90.
39. Rindi G, Villanacci V, Ubiali A, Scarpa A. Endocrine tumours of the digestive tract and pancreas: histogenesis, diagnosis and molecular basis. Expert Rev Mol Diagn 2001;1:323-33.
40. Heppner C, Kester MB, Agarwal SK, Debelenko LV, Emmert-Buck MR, Guru SC, et al. Somatic mutation of the MEN1 gene in parathyroid tumours. Nat Genet 1997;16:375-8.
41. Zhuang Z, Ezzat SZ, Vortmeyer AO, Weil R, Oldfield EH, Park WS, et al. Mutations of the MEN1 tumor suppressor gene in pituitary tumors. Cancer Res 1997;57:5446-51.
42. D'Adda T, Keller G, Bordi C, Hofler H. Loss of heterozygosity in 11q13-14 regions in gastric neuroendocrine tumours not associated with multiple endocrine neoplasia type 1 syndrome. Lab Invest 1999;79:671-7.
43. Görtz B, Roth J, Krahenmann A, de Krijger RR, Muletta-Feurer S, Rutimann K, et al. Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumours and not restricted to foregut neoplasms. Am J Pathol 1999;154:429-36.
44. D'Adda T, Pizzi S, Azzoni C, Bottarelli L, Crafa P, Pasquali C, et al. Different patterns of 11q allelic losses in digestive endocrine tumours. Hum Pathol 2002;33:322-9.
45. Beghelli S, Pelosi G, Zamboni G, Falconi M, Iacono C, Bordi C, et al. Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p. J Pathol 1998;186:41-50.
46. Lollgen RM, Hessman O, Szabo E, Westin G, Akerstrom G. Chromosome 18 deletions are common events in classical midgut carcinoid tumours. Int J Cancer 2001;92:812-5.
47. Tonnies H, Toliat MR, Ramel C, Pape UF, Neitzel H, Berger W, et al. Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation. Gut 2001;48:536-41.
48. D'Adda T, Candidus S, Denk H, Bordi C, Hofler H. Gastric neuroendocrine neoplasms: tumour clonality and malignancy-associated large X-chromosomal deletions. J Pathol 1999;189:394-401.
49. Pizzi S, D'Adda T, Azzoni C, Rindi G, Grigolato P, Pasquali C, et al. Malignancy-associated allelic losses on the X-chromosome in foregut but not in midgut endocrine tumours. J Pathol 2002;196:401-7.
50. Missiaglia E, Moore PS, Williamson J, Lemoine NR, Falconi M, Zamboni G, et al. Sex chromosome anomalies in pancreatic endocrine tumours. Int J Cancer 2002;98:532-8.
51. Lohmann DR, Funk A, Niedermeyer HP, Haupel S, Hofler H. Identification of p53 gene mutations in gastrointestinal and pancreatic carcinoids by nonradioisotopic SSCA. Virchows Arch B Cell Pathol Incl Mol Pathol 1993;64:293-6.
52. Lohmann D, Putz B, Reich U, Bohm J, Prauer H, Hofler H. Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathological data. Am J Pathol 1993;142:907-15.
53. Vortmeyer AO, Lubensky IA, Merino MJ, Wang CY, Pham T, Furth EE, et al. Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas. J Natl Cancer Inst 1997;89:1448-53.
54. Ubiali A, Benetti A, Papotti M, Villanacci V, Rindi G. Genetic alterations in poorly differentiated endocrine colon carcinomas developing in tubulo-villous adenomas: a report of two cases. Virchows Arch 2001;439:776-81.